Search for an orphan drug

NRXBF Gains Another Governmental Designation

The FDA has authority to grant orphan drug designation to a drug or biological product to prevent, diagnose or treat a rare disease or condition ...

Off-Label Use of Monoclonal Antibodies for Eosinophilic Esophagitis ...

Reslizumab inhibits eosinophil proliferation by targeting the IL-5 receptor's α chain on eosinophils. In 2007, it received Orphan Drug Designation from the FDA ...

Children in Gaza need life-saving support | UNICEF

Search area has closed. Search area has opened. SearchClose. Toggle ... Today, children in the Gaza Strip face the deadly effects of disease and malnutrition as ...

How logistics shape the success of rare disease trials

... orphan drug trials. Unlike conventional studies for common ... disease trials have to contend with fewer patients who can be difficult to find.

Congress must fix a law that's discouraging rare disease research

For those of us diagnosed with a rare disease, the Orphan Drug Act of 1982 has been a lighthouse of hope for a perilous journey. The ODA ...

Ionis Announces Pivotal Phase 3 Trial Design for ION582 in ...

... Search icon. Close. Ionis Pharmaceuticals ... In 2022, the U.S. Food and Drug Administration (FDA) granted ION582 Orphan Drug designation and Rare ...

What are Orphan Drugs? I Rare Diseases I Orphan ... - YouTube

In this video we explain the Orphan Drugs & Rare diseases along with the treatment and global landscape for funding, research and treatment ...

FDA Approves Nilotinib Formulation for Chronic Myeloid Leukemia

Drug Search · Check Drug ... The FDA granted priority review, breakthrough designation, and orphan drug designation for this application.

Gileads Livdelzi Seladelpar Demonstrated a Sustained Efficacy and ...

... Orphan Drug Designation for the treatment of people living with PBC. Seladelpar has also been accepted for review by the UK Medicines and ...

Grace Therapeutics Announces Second Fiscal Quarter 2025 ...

Careers Search · Grace Therapeutics, Inc. Homepage · About Us ... Grace Therapeutic's lead clinical assets have each been granted Orphan Drug ...

Third Quarter Earnings - Mereo BioPharma

Alvelestat has received U.S. Orphan Drug Designation for the treatment of AATD and Fast Track designation from the FDA. Following results from ...

Nipocalimab demonstrates significant clinical improvement in ...

U.S. FDA Orphan drug status for wAIHA in December 2019, HDFN in June ... search this site for more information. Do Not Sell or Share My ...

OS Therapies Reports Third Quarter 2024 Financial Results and ...

Search Query Submit Search. Press Releases. OS Therapies Reports ... Orphan Drug Designations by the FDA and European Medicines Agency (EMA).

OS Therapies Reports Third Quarter 2024 Financial Results and ...

... Orphan Drug Designations by the FDA and European Medicines Agency (EMA). ... Search. Search Options. Search All; Search News; Search Site ...

Osteal Therapeutics Announces Positive 12-Month Results from the ...

Search ... The US Food and Drug Administration has granted VT-X7 Breakthrough Therapy, Orphan Drug, Fast Track and Qualified Infectious Disease ...

FDA OKs clinical trial of ATA-200 gene therapy for LGMD children

... Search. Close drawer. What ... The treatment candidate was granted orphan drug status in both the European Union and the U.S. for LGMD2C/R5.

Koselugo showed statistically significant and clinically meaningful ...

Search Menu. Search. Search Search ... Koselugo is approved in the US, EU, Japan, China and other countries and has been granted Orphan Drug ...

OS Therapies Reports Third Quarter 2024 Financial Results and ...

... Orphan Drug Designations by the FDA and European Medicines Agency (EMA). ... Search · Advertise with the FTFollow the FT on XFT ChannelsFT ...

ISO 13485 - Quality Management System - BSI

Clinical Evaluation of Orphan Devices & MDCG 2024-10 ... Entered into force on 25 May 2017 with 26 May 2021 date of application. Find out more · Science, medicine ...

Immuneering Reports Third Quarter 2024 Financial Results

FDA Orphan Drug Designation for IMM-1-104 in the Treatment of Pancreatic Cancer: In October 2024, the U.S. Food and Drug Administration (FDA) ...